Inhibrx Biosciences' Q3 net loss widens, misses EPS estimates

Inhibrx Biosciences

14/11/2025 11:08

Overview

Inhibrx Q3 net loss widens, missing analyst expectations for EPS and net income

R&D expenses decreased due to reduced process development and headcount

Cash and cash equivalents decreased to $153.1 mln from $186.6 mln in Q2 2025

Outlook

Inhibrx plans to submit a biologics license application in Q2 2026

Interim data shows high response rates in colorectal cancer and Ewing sarcoma

Result Drivers

R&D EXPENSES - Decrease in R&D expenses due to reduced process development and manufacturing activities

CLINICAL TRIAL RESULTS - Positive topline results from ozekibart trial in chondrosarcoma, meeting primary endpoint

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 EPS
Miss
-$2.28
-$1.72 (1 Analyst)
Q3 Net Income
Miss
-$35.26 mln
-$26.61 mln (1 Analyst)
Q3 Operating Income
Miss
-$33.81 mln
-$28.98 mln (1 Analyst)
Q3 Operating Expenses
$33.81 mln


Analyst Coverage

The one available analyst rating on the shares is "hold"

Press Release: ID:nPnbkZVXga

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)